Delaying Alzheimer’s is worth trillions
Executive Summary
New drugs to delay the onset of Alzheimer's disease by five years would have a social benefit to Americans of as much as $4 trillion over the next four decades, according to a study sponsored by Accelerate Cure and Treatments for Alzheimer's Disease. A drug delaying onset of disease by one year would produce a benefit worth $1.2 billion over the same period. These findings demonstrate the benefits to be gained by giving promising Alzheimer's treatments "the same priority review" accorded drugs for diseases such as cancer and HIV/AIDS, ACT-AD Chair Daniel Perry contends...